September just clocked in—and it didn’t come to watch paint dry

Fresh catalysts. Sudden volume. Unexpected runners.

The market can go from dead quiet to “Wait… when did THAT happen?” pretty quickly.

That’s exactly why GuyStocks exists.

We’re watching for interesting momentum, unusual activity, and developing market stories that deserve a spot on your radar.

What hits your inbox:

• Real-time momentum alerts
• Unusual market activity
• Fast-moving stock stories
• Straight-to-the-point insights
• 100% free access

Don’t be the trader hearing about the move after everyone else is already talking about it.

👉 Join GuyStocks free and confirm your subscription to get on the alert list.
(By clicking the link above, you agree to receive emails from GuyStocks.com. You can opt out at any time. - Privacy Policy)

Palo Alto vs. Zscaler: Which Cybersecurity Stock Looks Stronger After Earnings?

Written by Sam Quirke. First Published: 9/7/2026.

The AI boom has been a gift to the cybersecurity industry, driving a wave of spending as companies scramble to defend against a new generation of threats. Two of the biggest beneficiaries, Palo Alto Networks Inc. (NASDAQ: PANW) and Zscaler Inc. (NASDAQ: ZS), both reported earnings this week, offering a rare chance to weigh the sector’s heavyweights side by side.

Curiously, both comfortably beat revenue and earnings expectations, yet both shares slipped afterward. Palo Alto had already rallied sharply from its February low heading into its report. Still, even a solid beat couldn’t stop the stock from falling sharply—a classic case of lofty expectations proving too difficult to satisfy. Zscaler, earlier in its own recovery after a punishing slide, edged lower as well, with its results apparently failing to impress investors.

Moderna Doubled in One Day. This Medical Stock Could Be Next (Ad)

Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.

It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.

Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States.

Click here to learn about this new era of medical technology

With both companies riding the same powerful tailwind and both leaving the market slightly underwhelmed this week, it’s a good time to examine which one enters the final few months of the year in the stronger position.

2 AI Security Winners Take Different Paths

Although they compete for the same security budgets, the two companies are known for very different things. Palo Alto has made its name as the great consolidator, with a strategy it calls platformization: persuading customers to buy a whole suite of security products from a single vendor rather than stitching together tools from many.

Zscaler, by contrast, made its name pioneering zero trust, a cloud-based security model that assumes no user or device should be trusted by default. While the approach is now industrywide, Zscaler remains its standard-bearer and has built a formidable cloud security franchise around it.

Both models are benefiting handsomely from the AI wave, and both companies used their results this week to highlight surging demand for AI-related security. However, the big difference lies in each company’s underlying momentum, and here the numbers begin to separate them.

The Growth Gap Starts to Show

On the measures that matter most, Palo Alto is coming out ahead this week. Its key gauge of recurring revenue from next-generation products soared 63% over the past year, a blistering pace for a company of its size. Zscaler’s equivalent measure grew a still-respectable 25%—solid by most standards, but visibly slower than its larger rival.

The platformization strategy also appears to be paying off handsomely. Palo Alto reported that customers who had consolidated onto its platform were spending more than 120% of what they had spent a year earlier, powerful evidence that the land-and-expand approach is working. Its total backlog of contracted future revenue also swelled past a symbolic threshold for the first time, underscoring strong demand.

Zscaler, for its part, pointed to record activity among its largest customers and strong adoption of its newer, more flexible pricing model. Yet its guidance for the year ahead implied a more measured growth trajectory, while its sales restructuring adds near-term uncertainty.

Cash Flow Separates the Cybersecurity Leaders

The gap widens further when it comes to turning growth into cash. Palo Alto generated an adjusted free cash flow margin of around 38%, an enviable figure that reflects the operating leverage of its sprawling platform. That torrent of cash gives it ample firepower to invest, acquire and reward shareholders.

Zscaler is no slouch on profitability and, in fact, reported a record operating margin of its own. But its full-year free cash flow margin, at around 23%, sits well below Palo Alto’s, dented in part by the timing of cash collection and heavier spending. For a company still scaling up, that’s understandable, but in a head-to-head comparison, it leaves Zscaler a step behind.

This is the crux of the comparison. Both are excellent businesses, but Palo Alto is generating more growth and more cash at a greater scale—precisely the combination that tends to reward long-term investors.

Palo Alto Makes the Stronger Post-Earnings Case

Weighing it all up, Palo Alto looks stronger based on this week’s evidence. Faster growth, superior cash generation and clear proof that its platform strategy is deepening customer relationships give it a more compelling setup heading into the rest of the year.

Given its significant outperformance of Zscaler so far this year, investors have been receiving that message for a while. For those of us on the sidelines weighing an entry into one or the other, the post-earnings dip in Palo Alto makes for an attractive entry point.

To be fair, both stocks carry a MarketBeat consensus rating of Moderate Buy, but Palo Alto has attracted particularly bullish attention this week. The team at Argus, for example, just gave it a fresh $425 price target, implying nearly 30% upside from current levels.

None of this makes Zscaler a poor investment. It remains a high-quality operator with a strong niche and a real AI tailwind of its own, and it could yet reward patient investors. However, for investors seeking a stronger combination of growth and profitability today, this week’s earnings made the stronger case for Palo Alto.

Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?

Written by Chris Markoch. First Published: 9/2/2026.

For a few days in mid-August, Wendy's (NASDAQ: WEN) traded like a company on the verge of being taken private. Reports surfaced on Aug. 12 that Trian Fund Management, Nelson Peltz's activist firm and a roughly 16% shareholder in Wendy's, was assembling a consortium to explore a buyout.

The stock ripped nearly 15% higher. That briefly pushed shares toward the $9 mark, putting WEN in positive territory for 2026.

Moderna Doubled in One Day. This Medical Stock Could Be Next (Ad)

Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.

It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.

Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States.

Click here to learn about this new era of medical technology

The move didn't last. Reuters reported that Trian had no current plans to bid, and the stock gave back the entire rally in a single session, sliding back toward the high-$7 range. Trian's stated reasoning, including concerns about performance, valuation and strategic direction, read less like a passing decision and more like a well-capitalized insider declining to catch a falling knife.

That reversal came at a time when Wendy's was already struggling. In its Q2 2026 earnings report, delivered on Aug. 7, Wendy's reported a 7% drop in U.S. same-restaurant sales, a 41% decline in net income and a withdrawn full-year 2026 outlook. CEO Bob Wright didn't sugarcoat the results, telling investors that performance was "not at our potential."

But that's not quite where the story ends. In the weeks since, WEN has quietly clawed back most of that decline. That recovery is why investors should take the rally seriously, rather than dismissing it as mere rhetoric.

Why WEN Started Trading Like a Meme Stock

Five years ago, Wendy's was trading at an all-time high of around $25. Since then, WEN has been in a steep decline, bringing the stock to around $6.22 per share in June 2026. That put it perilously close to penny-stock territory.

The decline hasn't been without merit. The quick-service restaurant industry has struggled to find the right mix of price and value for an increasingly stretched core consumer. Wendy's hasn't helped matters with execution errors.

So why did WEN soar 15% in such a brief period? It wasn't all about Trian. More than 32% of its float was sold short. Savvy traders saw an opportunity to force some of those short sellers to cover their positions. The move may not technically qualify as a short squeeze, but that term helps explain why the stock moved so sharply.

This is an important distinction for investors. A stock with substantial short interest can move dramatically on relatively little new information. When sentiment is already heavily skewed to the bearish side, even a temporary positive catalyst can force traders to reassess their positions.

That doesn't necessarily mean the underlying business has improved.

It does, however, mean that WEN can remain unusually volatile as investors debate whether the worst of the company's decline has already been priced into the stock.

Wendy's Stock Technical Analysis Shows a Bullish Setup, But Not a Confirmed Turnaround

However, just as it did in early July, investors considering a position in WEN should watch the chart. The stock appears to be finding support at an ascending 50-day simple moving average, which could mark the start of a bullish move.

The technical picture is particularly interesting because WEN has recovered from the initial Trian-related reversal rather than simply falling back to its June lows.

That creates a potential test for the bulls. If shares can continue holding above the 50-day moving average and establish higher lows, traders will have a technical argument that the longer-term downtrend may be losing some of its force. Conversely, a decisive break below that moving average would weaken the bullish setup and suggest that the recent recovery was another temporary bounce.

The MACD may be the deciding factor. In recent months, momentum has clearly been on the bulls' side. The coming weeks will determine whether that momentum was due to the Trian news or whether investors see a genuine opportunity.

For technical traders, the distinction matters. Momentum that survives the removal of a major catalyst is generally more meaningful than momentum that disappears as soon as the catalyst does.

Why Betting Against WEN May Be the Wrong Bet

Wendy's is giving investors a genuinely mixed picture. At around 12 times earnings, WEN is overvalued by some measures.

Many investors won't get excited about the stock until the company starts showing positive year-over-year earnings.

That said, Wendy's has been clearing a low bar for earnings over the past several quarters.

Institutions have also been buying the stock. That wouldn't happen if they believed the company's outlook was hopeless. Instead, their purchases appear to reflect a calculation that the sell-off has been overdone.

That buying activity is directly contradicted by analyst sentiment, which leans bearish with a consensus Reduce rating. Furthermore, of the 21 analysts that MarketBeat tracks, six have a Sell rating on WEN.

So, Was the Rally Ever Real?

The honest answer is yes—partly. The initial 15% pop was driven mostly by enthusiasm for the deal and short covering. That part of the move was always likely to unwind once Trian stepped back.

The subsequent recovery to the mid-$8 range looks different. It appears more like value buyers and technical traders stepping in at a level where the stock had already priced in a great deal of bad news.

The catch is that, without Trian as a backstop, there's no buyout floor left under the stock. Whatever happens from here rests entirely on Wright's turnaround plan actually working. The chart says momentum currently favors the bulls. The fundamentals say that momentum still has something to prove.